scholarly journals Correction to: Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections

2021 ◽  
Author(s):  
Timo Huber ◽  
Philipp Steininger ◽  
Pascal Irrgang ◽  
Klaus Korn ◽  
Matthias Tenbusch ◽  
...  
Keyword(s):  
Diagnostic Performance ◽  
Respiratory Infections ◽  
Antibody Assays ◽  
Viral Respiratory Infections ◽  
Viral Respiratory

scholarly journals The lung–gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes

2021 ◽  
Author(s):  
Valentin Sencio ◽  
Marina Gomes Machado ◽  
François Trottein
Keyword(s):  
Gut Microbiota ◽  
Bacterial Infections ◽  
Respiratory Infections ◽  
Critical Role ◽  
Good Health ◽  
Disease Outcomes ◽  
And Function ◽  
Viral Respiratory Infections ◽  
The Impact ◽  
Viral Respiratory

AbstractBacteria that colonize the human gastrointestinal tract are essential for good health. The gut microbiota has a critical role in pulmonary immunity and host’s defense against viral respiratory infections. The gut microbiota’s composition and function can be profoundly affected in many disease settings, including acute infections, and these changes can aggravate the severity of the disease. Here, we discuss mechanisms by which the gut microbiota arms the lung to control viral respiratory infections. We summarize the impact of viral respiratory infections on the gut microbiota and discuss the potential mechanisms leading to alterations of gut microbiota’s composition and functions. We also discuss the effects of gut microbial imbalance on disease outcomes, including gastrointestinal disorders and secondary bacterial infections. Lastly, we discuss the potential role of the lung–gut axis in coronavirus disease 2019.

scholarly journals COVID-19 mitigation strategies were associated with decreases in other respiratory virus infections

2021 ◽  
Author(s):  
Sinha Pranay ◽  
Katherine Reifler ◽  
Michael Rossi ◽  
Manish Sagar
Keyword(s):  
Respiratory Virus ◽  
Respiratory Infections ◽  
Respiratory Viruses ◽  
Mitigation Strategies ◽  
Virus Infections ◽  
Time Period ◽  
Viral Respiratory Infections ◽  
Respiratory Virus Infections ◽  
Viral Respiratory

Abstract Detection of diverse respiratory viruses in Boston was around 80% lower after practices were instituted to limit COVID-19 spread compared to the same time period during the previous five years. Continuing the strategies that lower COVID-19 dissemination may be useful in decreasing the incidence of other viral respiratory infections.

scholarly journals Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections

2021 ◽  
Author(s):  
Timo Huber ◽  
Philipp Steininger ◽  
Pascal Irrgang ◽  
Klaus Korn ◽  
Matthias Tenbusch ◽  
...  
Keyword(s):  
Legionella Pneumophila ◽  
False Positive ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Chlamydia Psittaci ◽  
Specific Flow ◽  
Antibody Assays ◽  
Positive Results ◽  
Viral Respiratory

AbstractSARS-CoV-2 antibody assays are used for epidemiological studies and for the assessment of vaccine responses in highly vulnerable patients. So far, data on cross-reactivity of SARS-CoV-2 antibody assays is limited. Here, we compared four enzyme-linked immunosorbent assays (ELISAs; Vircell SARS-CoV-2 IgM/IgA and IgG, Euroimmun SARS-CoV-2 IgA and IgG) for detection of anti-SARS-CoV-2 antibodies in 207 patients with COVID-19, 178 patients with serological evidence of different bacterial infections, 107 patients with confirmed viral respiratory disease, and 80 controls from the pre-COVID-19 era. In COVID-19 patients, the assays showed highest sensitivity in week 3 (Vircell-IgM/A and Euroimmun-IgA: 78.9% each) and after week 7 (Vircell-IgG: 97.9%; Euroimmun-IgG: 92.1%). The antibody indices were higher in patients with fatal disease. In general, IgM/IgA assays had only limited or no benefit over IgG assays. In patients with non-SARS-CoV-2 respiratory infections, IgG assays were more specific than IgM/IgA assays, and bacterial infections were associated with more false-positive results than viral infections. The specificities in bacterial and viral infections were 68.0 and 81.3% (Vircell-IgM/IgA), 84.8 and 96.3% (Euroimmun-IgA), 97.8 and 86.0% (Vircell-IgG), and 97.8 and 99.1% (Euroimmun-IgG), respectively. Sera from patients positive for antibodies against Mycoplasma pneumoniae, Chlamydia psittaci, and Legionella pneumophila yielded particularly high rates of unspecific false-positive results in the IgM/IgA assays, which was revealed by applying a highly specific flow-cytometric assay using HEK 293 T cells expressing the SARS-CoV-2 spike protein. Positive results obtained with anti-SARS-CoV-2 IgM/IgA ELISAs require careful interpretation, especially if there is evidence for prior bacterial respiratory infections.

scholarly journals Spatial and Temporal Spread of Acute Viral Respiratory Infections in Young Children Living in High-altitude Rural Communities

2016 ◽  
Vol 35 (10) ◽  
pp. 1057-1061 ◽  
Author(s):  
Charlotte Buehler Cherry ◽  
Marie R. Griffin ◽  
Kathryn M. Edwards ◽  
John V. Williams ◽  
Ana I. Gil ◽  
...  
Keyword(s):  
Rural Communities ◽  
Young Children ◽  
High Altitude ◽  
Respiratory Infections ◽  
Viral Respiratory Infections ◽  
Viral Respiratory ◽  
Temporal Spread

scholarly journals Etiology of acute viral respiratory infections common in Pakistan: A review

2018 ◽  
pp. e2024 ◽  
Author(s):  
Riffat Naz ◽  
Asma Gul ◽  
Urooj Javed ◽  
Alina Urooj ◽  
Sidra Amin ◽  
...  
Keyword(s):  
Respiratory Infections ◽  
Viral Respiratory Infections ◽  
Viral Respiratory

Outcomes of Acute Myocardial Infarction in Patients with Influenza and Other Viral Respiratory Infections

2019 ◽  
Vol 132 (10) ◽  
pp. 1173-1181 ◽  
Author(s):  
Pimprapa Vejpongsa ◽  
Danai Kitkungvan ◽  
Mohammad Madjid ◽  
Konstantinos Charitakis ◽  
H. Vernon Anderson ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Respiratory Infections ◽  
Viral Respiratory Infections ◽  
Viral Respiratory

scholarly journals Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections

2021 ◽  
Vol 12 ◽  
Author(s):  
Amos C. Lee ◽  
Yunjin Jeong ◽  
Sumin Lee ◽  
Haewook Jang ◽  
Allen Zheng ◽  
...  
Keyword(s):  
Interferon Beta ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Type I ◽  
Emerging Viruses ◽  
Respiratory Viral Infection ◽  
Respiratory Viral Infections ◽  
Viral Respiratory Infections ◽  
Viral Respiratory

In addition to SARS-CoV-2 and its variants, emerging viruses that cause respiratory viral infections will continue to arise. Increasing evidence suggests a delayed, possibly suppressed, type 1 interferon (IFN-I) response occurs early during COVID-19 and other viral respiratory infections such as SARS and MERS. These observations prompt considering IFN-β as a prophylactic or early intervention for respiratory viral infections. A rationale for developing and testing intranasal interferon beta (IFN-β) as an immediately available intervention for new respiratory viral infections that will arise unexpectedly in the future is presented and supported by basic and clinical trial observations. IFN-β prophylaxis could limit the spread and consequences of an emerging respiratory viral infection in at-risk individuals while specific vaccines are being developed.

Sign in / Sign up

Export Citation Format

Share Document